Review of mass spectrometry-based metabolomics in cancer research

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 12, 2013, Pages 2182-2201

  Liesenfeld, David B ^a   Habermann, Nina ^a   Owen, Robert W ^a   Scalbert, Augustin ^b   Ulrich, Cornelia M ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

27 NOR 5BETA CHOLESTANE 3,7,12,24,25 PENTOL GLUCURONIDE; 5 HYDROXYTRYPTOPHAN; AROMATIC HYDROCARBON RECEPTOR; CA 125 ANTIGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; GLUCURONIDE; GLUTAMIC ACID; GLUTAMINE; GLYCEROLIPID; IMATINIB; INDOLE; INDOLEACETIC ACID; INOSITOL; KYNURENINE; LYSOPHOSPHATIDYLCHOLINE; N ACETYLGLUCOSAMINE; NICOTINURIC ACID; PHENYLALANINE; POLYUNSATURATED FATTY ACID; PROSTATE SPECIFIC ANTIGEN; PURINE; STEROID; TAUROCHOLIC ACID; TEMOZOLOMIDE; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; TYROSINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; AMINO ACID METABOLISM; ANDROGEN DEPRIVATION THERAPY; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER TISSUE; CASE CONTROL STUDY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DATA ANALYSIS; DEVELOPMENTAL STAGE; DNA METHYLATION; EARLY DIAGNOSIS; ENERGY METABOLISM; ESOPHAGUS CANCER; FATTY ACID SYNTHESIS; GAS CHROMATOGRAPHY; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIPID METABOLISM; LIPID OXIDATION; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MASS SPECTROMETRY; MELANOMA; METABOLOMICS; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CANCER; NUCLEOTIDE METABOLISM; OVARY CANCER; PANCREAS CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PURINE METABOLISM; REVIEW; SARCOMA; STANDARDIZATION; STEROID BLOOD LEVEL; STOMACH CANCER; TRYPTOPHAN METABOLISM; TUMOR CLASSIFICATION; URINALYSIS; UTERINE CERVIX CANCER;

HUMANS; MASS SPECTROMETRY; METABOLOMICS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890021455     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0584     Document Type: Review

References (154)

1. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 2002;48:155-71.
2. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol 1998;16:373-8.
3. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-9.
4. Fiehn O, Kopka J, Dormann P, Altmann T, Trethewey RN, Willmitzer L. Metabolite profiling for plant functional genomics. Nat Biotechnol 2000;18:1157-61.
5. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0-The human metabolome database in 2013. Nucleic Acids Res 2013;41:D801-7.
6. Mal M, Koh PK, Cheah PY, Chan ECY. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry. Anal Bioanal Chem 2012;403:483-93.
7. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012;13:263-9.
8. Dettmer K, Hammock BD. Metabolomics - a new exciting field within the "omics" sciences. Environ Health Perspect 2004;112:A396-7.
9. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004;4:551-61.
10. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009;15:431-40.
11. Tang B, Hsu PY, Huang TH, Jin VX. Cancer omics: from regulatory networks to clinical outcomes. Cancer Lett 2012 Nov 29. [Epub ahead of print]
12. Hanash S, Taguchi A. The grand challenge to decipher the cancer proteome. Nat Rev Cancer 2010;10:652-60.
13. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-24.
14. Pavlou MP, Diamandis EP. The cancer cell secretome: a good source for discovering biomarkers? J Proteomics 2010;73:1896-906.
15. Nordstrom A, Lewensohn R. Metabolomics: moving to the clinic. J Neuroimmune Pharmacol 2010;5:4-17.
16. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011;27:431-2.
17. Karnovsky A, Weymouth T, Hull T, Tarcea VG, Scardoni G, Laudanna C, et al. Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data. Bioinformatics 2012;28:373-80.
18. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012;40:D109-14.
19. Locasale JW, Melman T, Song SS, Yang XM, Swanson KD, Cantley LC, et al. Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma. Mol Cell Proteomics 2012;11: M111.014688.
20. Wibom C, Surowiec I, Moren L, Bergstrom P, Johansson M, Antti H, et al. Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study. J Proteome Res 2010;9: 2909-19.
21. Gaspar EM, Lucena AF, Duro da Costa J, Chaves das Neves H. Organic metabolites in exhaled human breath-A multivariate approach for identification of biomarkers in lung disorders. J Chromatogr A 2009;1216:2749-56.
22. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 2010;6:78-95.
23. Cao HC, Huang HJ, Xu W, Chen DY, Yu J, Li J, et al. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. Anal Chim Acta 2011;691:68-75.
24. Abaffy T, Duncan R, Riemer DD, Tietje O, Elgart G, Milikowski C, et al. Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process. PLoSONE 2010;5:e13813.
25. Wedge DC, Allwood JW, Dunn W, Vaughan AA, Simpson K, Brown M, et al. Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with smallcell lung cancer. Anal Chem 2011;83:6689-97.
26. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007;26:51-78.
27. Lin L, Yu QA, Yan XM, Hang W, Zheng JX, Xing JC, et al. Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. Analyst 2010;135:2970-8.
28. Lokhov PG, Dashtiev MI, Bondartsov LV, Lisitsa AV, Moshkovskii SA, Archakov AI. Metabolic fingerprinting of blood plasma from patients with prostate cancer. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry 2010;4:37-41.
29. Yoo BC, Kong SY, Jang SG, Kim KH, Ahn SA, Park WS, et al. Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling. BMC Cancer 2010;10:55.
30. Ritchie SA, Ahiahonu PWK, Jayasinghe D, Heath D, Liu J, Lu YS, et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 2010;8:13.
31. Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE 2012;7:e40459.
32. Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, et al. Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res 2012;11:1354-63.
33. Budczies J, Denkert C, Muller BM, Brockmoller SF, Klauschen F, Gyorffy B, et al. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. BMC Genomics 2012;13:334.
34. Maeda J, Higashiyama M, Imaizumi A, Nakayama T, Yamamoto H, Daimon T, et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer 2010;10:690.
35. Chen J, Zhang X, Cao R, Lu X, Zhao S, Fekete A, et al. Serum 27-nor-5beta-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res 2011;10:2625-32.
36. Brown MV, McDunn JE, Gunst PR, Smith EM, Milburn MV, Troyer DA, et al. Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies. Genome Med 2012;4:33.
37. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006;66:10795-804.
38. Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T, et al. Metabolite profiling of human colon carcinoma - Deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008;7:72.
39. Hori S, Nishiumi S, Kobayashi K, Shinohara M, Hatakeyama Y, Kotani Y, et al. A metabolomic approach to lung cancer. Lung Cancer 2011;74:284-92.
40. Wu H, Xue R, Tang Z, Deng C, Liu T, Zeng H, et al. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Anal Bioanal Chem 2010;396:1385-95.
41. Lin L, Huang ZZ, Gao Y, Yan XM, Xing JC, Hang W. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J Proteome Res 2011;10:1396-405.
42. Song H, Wang L, Liu HL, Wu XB, Wang HS, Liu ZH, et al. Tissue metabolomic fingerprinting reveals metabolic disorders associated with human gastric cancer morbidity. Oncol Rep 2011;26:431-8.
43. Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLCQTOFMS. J Proteome Res 2009;8:4844-50.
44. Jiye A, Qian S, Wang G, Yan B, Zhang S, Huang Q, et al. Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. PLoS ONE 2010;5: e13186.
45. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of menduring their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res 2012;18:3677-85.
46. Cai XM, Dong J, Zou LJ, Xue XY, Zhang XL, Liang XM. Metabonomic study of lung cancer and the effects of radiotherapy on lung cancer patients: analysis of highly polar metabolites by ultraperformance HILIC coupled with Q-TOF MS. Chromatographia 2011;74:391-8.
47. Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H, et al. Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res 2012;11:4361-72.
48. Aa J, Yu L, Sun M, Liu L, Li M, Cao B, et al. Metabolic features of the tumor microenvironment of gastric cancer and the link to the systemic macroenvironment. Metabolomics 2012;8:164-73.
49. Jobu K, Sun CH, Yoshioka S, Yokota J, Onogawa M, Kawada C, et al. Metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer. Biol Pharm Bull 2012;35:639-42.
50. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009;8:558-70.
51. Ma YL, Qin HL, Liu WJ, Peng JY, Huang L, Zhao XP, et al. Ultra-high performance liquid chromatography-mass spectrometry for the metabolomic analysis of urine in colorectal cancer. Dig Dis Sci 2009;54:2655-62.
52. Silva EG, Lopez PR, Atkinson EN, Fente CA. A new approach for identifying patients with ovarian epithelial neoplasms based on highresolution mass spectrometry. Am J Clin Pathol 2010;134:903-9.
53. Farshidfar F, Weljie AM, Kopciuk K, Buie WD, MacLean A, Dixon E, et al. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med 2012;4:42.
54. Tang F, Xie C, Huang D, Wu Y, Zeng M, Yi L, et al. Novel potential markers of nasopharyngeal carcinoma for diagnosis and therapy. Clin Biochem 2011;44:711-8.
55. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GAN, Owusu-Sarfo K, Ballas RA, et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 2010;70:8309-18.
56. Peters FT, Remane D. Aspects of matrix effects in applications of liquid chromatography-mass spectrometry to forensic and clinical toxicology - a review. Anal Bioanal Chem 2012;403:2155-72.
57. Want E, Masson P. Processing and analysis of GC/LC-MS-based metabolomics data. Methods Mol Biol 2011;708:277-98.
58. Castillo S, Gopalacharyulu P, Yetukuri L, Orešič M. Algorithms and tools for the preprocessing of LC-MS metabolomics data. Chemom Intell Lab Syst 2011;108:23-32.
59. Lommen A. Data (pre-)processing of nominal and accurate mass LCMS or GC-MS data using MetAlign. Methods Mol Biol 2012;860: 229-53.
60. Pluskal T, Castillo S, Villar-Briones A, Oresic M. MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 2010;11:395.
61. An ZL, Chen YH, Zhang RP, Song YM, Sun JH, He JM, et al. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer. J Proteome Res 2010;9:4071-81.
62. Chen YH, Zhang RP, Song YM, He JM, Sun JH, Bai JF, et al. RRLCMS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst 2009;134:2003-11.
63. Frickenschmidt A, Frohlich H, Bullinger D, Zell A, Laufer S, Gleiter CH, et al. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers 2008;13:435-49.
64. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006;5:64.
65. Wang WZ, Feng B, Li XA, Yin PY, Gao P, Zhao XJ, et al. Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry. Mol Biosyst 2010;6:1947-55.
66. Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:59-65.
67. Warrack BM, Hnatyshyn S, Ott K-H, Reily MD, Sanders M, Zhang H, et al. Normalization strategies for metabonomic analysis of urine samples. J Chromatogr B 2009;877:547-52.
68. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int 2010;78:486-94.
69. Danielsson R, Allard E, Sjoberg PJR, Bergquist J. Exploring liquid chromatography-mass spectrometry fingerprints of urine samples from patients with prostate or urinary bladder cancer. Chemom Intell Lab Syst 2011;108:33-48.
70. Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, Macdonald IA, et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem 2006;78:567-74.
71. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011;6:1060-83.
72. Nam H, Chung BC, Kim Y, Lee K, Lee D. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 2009;25:3151-7.
73. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
74. Guan W, Zhou M, Hampton CY, Benigno BB, Walker LD, Gray A, et al. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinformatics 2009;10:259.
75. Henneges C, Bullinger D, Fux R, Friese N, Seeger H, Neubauer H, et al. Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection. BMC Cancer 2009;9:104.
76. Kim Y, Koo I, Jung BH, Chung BC, Lee D. Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinformatics 2010;11 Suppl 2:S4.
77. Chen J, Zhang Y, Zhang X, Cao R, Chen S, Huang Q, et al. Application of L-EDA in metabonomics data handling: Global metabolite profiling and potential biomarker discovery of epithelial ovarian cancer prognosis. Metabolomics 2011;7:614-22.
78. Sumner L, Amberg A, Barrett D, Beale M, Beger R, Daykin C, et al. Proposed minimum reporting standards for chemical analysis. Metabolomics 2007;3:211-21.
79. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011;10:M110 004945.
80. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res 2011;71:7376-86.
81. Ng D, Pasikanti K, Chan E. Trend analysis of metabonomics and systematic review of metabonomics-derived cancer marker metabolites. Metabolomics 2011;7:155-78.
82. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
83. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880-8.
84. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197-203.
85. Xie GX, Chen TL, Qiu YP, Shi P, Zheng XJ, Su MM, et al. Urine metabolite profiling offers potential early diagnosis of oral cancer. Metabolomics 2012;8:220-31.
86. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science 2012;336: 1262-7.
87. Zhu Q, Gao R, Wu W, Qin H. The role of gut microbiota in the pathogenesis of colorectal cancer. Tumour Biol 2013;34:1285-300.
88. McGarr SE, Ridlon JM, Hylemon PB. Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastroenterol 2005;39:98-109.
89. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
90. Leichtle AB, Nuoffer JM, Ceglarek U, Kase J, Conrad T, Witzigmann H, et al. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics 2012;8:643-53.
91. Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 2011;6:e24143.
92. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007;104:19345-50.
93. Bullinger D, Frohlich H, Klaus F, Neubauer H, Frickenschmidt A, Henneges C, et al. Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. Anal Chim Acta 2008;618:29-34.
94. Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011;71: 6590-600.
95. Zhou LN, Wang QC, Yin PY, Xing WB, Wu ZM, Chen SL, et al. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem 2012;403:203-13.
96. Lv WW, Yang TS. Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC-MS and multivariate statistical analysis. Clin Biochem 2012;45:127-33.
97. Kondo Y, Nishiumi S, Shinohara M, Hatano N, Ikeda A, Yoshie T, et al. Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomark Med 2011;5:451-60.
98. Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, et al. Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer 2012;130:2791-800.
99. Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, et al. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS ONE 2010;5:e14175.
100. Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009;5:868-76.
101. Wang BH, Chen DY, Chen Y, Hu ZH, Cao M, Xie Q, et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res 2012;11:1217-27.
102. Tan Y, Yin P, Tang L, Xing W, Huang Q, Cao D, et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics 2012;11:M111.010694.
103. Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta 2012;743:90-100.
104. Green TR, Fellman JH, Eicher AL, Pratt KL. Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils. Biochim Biophys Acta 1991;1073:91-7.
105. Arlt W, Biehl M, Taylor AE, Hahner S, Libe R, Hughes BA, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011;96:3775-84.
106. Kotlowska A, Sworczak K, Stepnowski P. Urinemetabolomics analysis for adrenal incidentaloma activity detection and biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:359-63.
107. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013;27:836-52.
108. Ma Y, Zhang P, Wang F, Liu W, Yang J, Qin H. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Ann Surg 2012;255:720-30.
109. Brockmöller SF, Bucher E, Muller BM, Budczies J, Hilvo M, Griffin JL, et al. Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. J Proteome Res 2012;11:850-60.
110. Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, et al. Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. Oncol Rep 2011;25:1005-12.
111. Woo HM, Kim KM, Choi MH, Jung BH, Lee J, Kong G, et al. Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 2009;400:63-9.
112. Chen F, Xue JH, Zhou LF, Wu SS, Chen Z. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem 2011;401:1899-904.
113. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 2010;47:282.
114. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8; discussion 20-1.
115. Fiehn O, Kristal B, van Ommen B, Sumner LW, Sansone SA, Taylor C, et al. Establishing reporting standards for metabolomic and metabonomic studies: a call for participation. OMICS 2006;10:158-63.
116. Chan EC, Pasikanti KK, Nicholson JK. Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nat Protoc 2011;6:1483-99.
117. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009;69:4918-25.
118. Ma YL, Liu WJ, Peng JY, Huang L, Zhang P, Zhao XP, et al. A pilot study of gas chromatograph/mass spectrometry-based serum metabolic profiling of colorectal cancer after operation. Mol Biol Rep 2010;37:1403-11.
119. Krug S, Kastenmuller G, Stuckler F, Rist MJ, Skurk T, Sailer M, et al. The dynamic range of the human metabolome revealed by challenges. FASEB J 2012;26:2607-19.
120. Dong J, Cai XM, Zou LJ, Chen C, Xue XY, Zhang XL, et al. Lysophosphatidylcholine biomarkers of lung cancer detected by ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Chem Res Chin Univ 2011;27:750-5.
121. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
122. Bory C, Boulieu R, Chantin C, Mathieu M. Diagnosis of alcaptonuria: rapid analysis of homogentisic acid by HPLC. Clin Chim Acta 1990;189:7-11.
123. Marescau B, De Deyn PP, Holvoet J, Possemiers I, Nagels G, Saxena V, et al. Guanidino compounds in serum and urine of cirrhotic patients. Metabolism 1995;44:584-8.
124. Yu LZ, Aa JY, Xu J, Sun M, Qian SX, Cheng LP, et al. Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol 2011;26:1290-7.
125. Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr 2012;26:548-58.
126. Lin L, Huang ZZ, Gao Y, Chen YJ, Hang W, Xing JC, et al. LC-MSbased serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery. Proteomics 2012;12:2238-46.
127. Silva CL, Passos M, Cmara JS. Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry. Br J Cancer 2011;105:1894-904.
128. Kelly AD, Breitkopf SB, Yuan M, Goldsmith J, Spentzos D, Asara JM. Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma. PLoS One 2011;6:e25357.
129. Huang Z, Lin L, Gao Y, Chen Y, Yan X, Xing J, et al. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol Cell Proteomics 2011;10:M111 007922.
130. Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res 2010;9:2988-95.
131. Issaq HJ, Nativ O, Waybright T, Luke B, Veenstra TD, Issaq EJ, et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 2008;179:2422-6.
132. Gu HW, Pan ZZ, Xi BW, Asiago V, Musselman B, Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer. Anal Chim Acta 2011;686:57-63.
133. Qiu YP, Cai GX, Su MM, Chen TL, Liu YM, Xu Y, et al. Urinary metabonomic study on colorectal cancer. J Proteome Res 2010;9: 1627-34.
134. Mal M, Koh PK, Cheah PY, Chan ECY. Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid Commun Mass Spectrom 2009;23:487-94.
135. Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 2009;8:352-61.
136. Song H, Peng JS, Yao DS, Yang ZL, Liu HL, Zeng YK, et al. Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res 2012;45:78-85.
137. Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, et al. Serum metabolomics reveals gamma-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol 2011;55:896-905.
138. Chen J, Wang W, Lv S, Yin P, Zhao X, Lu X, et al. Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta 2009;650:3-9.
139. Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 2009;648: 98-104.
140. Dong J, Cai XM, Zhao LL, Xue XY, Zou LJ, Zhang XL, et al. Lysophosphatidylcholine profiling of plasma: discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics 2010;6:478-88.
141. Yang Q, Shi X, Wang Y, Wang W, He H, Lu X, et al. Urinary metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system. J Sep Sci 2010;33: 1495-503.
142. Fan TWM, Lane AN, Higashi RM, Bousamra IM, Kloecker G, Miller DM. Metabolic profiling identifies lung tumor responsiveness to erlotinib. Exp Mol Pathol 2009;87:83-6.
143. Fan TWM, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, et al. Altered regulation of metabolic pathways in human lung cancer discerned by C-13 stable isotope-resolved metabolomics (SIRM). Mol Cancer 2009;8:41.
144. Yi LZ, Li DJ, Li XH, Deng JH, Liao YP, Liang YZ, et al. Serummetabolic fingerprinting to detect human nasopharyngeal carcinoma based on gas chromatography-mass spectrometry and partial least squareslinear discriminant analysis. Anal Lett 2011;44:1473-88.
145. Zhang Z, Qiu Y, Hua Y, Wang Y, Chen T, Zhao A, et al. Serum and urinary metabonomic study of human osteosarcoma. J Proteome Res 2010;9:4861-8.
146. Yan SK, Wei BJ, Lin ZY, Yang Y, Zhou ZT, Zhang WD. Ametabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. Oral Oncol 2008;44:477-83.
147. Fan LJ, Zhang W, Yin MZ, Zhang T, Wu XY, Zhang HY, et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MSplatform. Acta Oncol 2012;51:473-9.
148. Zhang T, Wu XY, Yin MZ, Fan LJ, Zhang HY, Zhao FL, et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta 2012;413:861-8.
149. Catchpole G, Platzer A, Weikert C, Kempkensteffen C, Johannsen M, Krause H, et al. Metabolic profiling reveals key metabolic features of renal cell carcinoma. J Cell Mol Med 2011;15:109-18.
150. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 2007;363:185-95.
151. Nishiumi S, Shinohara M, Ikeda A, Yoshie T, Hatano N, Kakuyama S, et al. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics 2010;6:518-28.
152. Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom 2010;24:613-20.
153. Wu H, Xue R, Lu C, Deng C, Liu T, Zeng H, et al. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3111-7.
154. Zhao XJ, Wang WZ, Wang JS, Yang J, Xu GW. Urinary profiling investigation of metabollites with cis-diol structure from cancer patients based on UPLC-MS and HPLC-MS as well as multivariate statistical analysis. J Sep Sci 2006;29:2444-51.